TICAGRELOR CAS 274693-27-5

icagrelor is a new kind of antiplatelet aggregation drug

Medical uses

Ticagrelor is used for the prevention of thrombotic events (for example stroke or heart attack)

in people with acute coronary syndrome or myocardial infarction with ST elevation. The drug

is combined with acetylsalicylic acid unless the latter is contraindicated. There is no high quality

evidence for the use of ticagrelor in non-ST elevation acute coronary syndrome.The FDA indication

for ticagrelor is reduction of the rate of cardiovascular death, myocardial infarction (MI), and stroke

in people with acute coronary syndrome or history of myocardial infarction.[citation needed]

AHA/ACC Guidelines (09/2014) state: “It is reasonable to choose ticagrelor over clopidogrel for

P2Y12 inhibition treatment in patients with NSTE-ACS treated with early invasive strategy

and/or coronary stenting”.

Ticagrelor was found to be comparable to acetylsalicylic acid in people with acute ischemic

stroke or transient ischemic attack.

Ticagrelor is a nucleoside analogue: the cyclopentane ring is similar to the sugar ribose, and the

nitrogen rich aromatic ring system resembles the nucleobase purine, giving the molecule an overall

similarity to adenosine. The substance has low solubility and low permeability under the 

Biopharmaceutics Classification System.